Key Companies in the Neurovascular Devices Market

Why Neurovascular Devices Market Is Expanding?

The Global Neurovascular Devices Market is on a robust growth trajectory, rising from USD 5.17 billion in 2025 to a projected USD 10.48 billion by 2035, at a CAGR of 8.22% over the 2026–2035 forecast period. Market Research Future (MRFR) identifies two co-equal primary demand engines: the expansion of mechanical thrombectomy guidelines from a 6-hour to a 24-hour treatment window, which approximately tripled the addressable patient pool in the United States, and an estimated USD 2.8 billion in cumulative venture investment directed toward next-generation stroke treatment devices between 2022 and 2025.

The convergence of aging demographics, rising global stroke incidence, and reimbursement broadening across Medicare and Japan's National Health Insurance provides self-reinforcing structural tailwinds that sustain above-baseline growth well through the 2035 forecast horizon.

The World Health Organization projects that between 2025 and 2035, the incidence of stroke would increase by 25% worldwide due to population aging in OECD countries and an increase in metabolic risk in low- and middle-income countries. Every year, there are about 150,000 more prospective candidates for endovascular neurology devices for every percentage point increase in stroke incidence. With over 30 randomized trials and a multi-decade evidence base, aneurysm coiling and embolization devices hold the largest product segment at 34.8% of the market.

The fastest-growing product category is neurothrombectomy devices, which will grow at a 9.14% CAGR through 2035 thanks to revised AHA/ASA guidelines that support mechanical thrombectomy within a 24-hour timeframe. Because stroke is the second most common cause of mortality worldwide, ischemic stroke therapies account for 53.5% of all treatments. Hospitals account for 63% of the market by end user, and as payer approvals for outpatient cerebrovascular procedures mount, ambulatory surgery centers are the fastest-growing channel at a 9.37% CAGR.

Why These Companies Are Leading the Market?

Four structural elements are identified by MRFR as defining category leadership in the Neurovascular Devices Market: geographic scope and regulatory footprint across FDA, CE mark, and NMPA (China) jurisdictions; clinical evidence depth and physician training legacy that generate switching costs; endovascular portfolio breadth encompassing embolic coils, stent retrievers, flow diverters, and aspiration catheters; and disciplined M&A strategy to acquire complementary neurovascular assets that expand technology moats and distribution density.

Medtronic's market leadership is defined by the breadth of its portfolio. Its Pipeline Flex embolization device and Solitaire X stent retriever cover the two biggest revenue sectors, aneurysm coiling and ischemic stroke thrombectomy, giving it an estimated 18–22% global revenue share. Stryker stands out for its clinical data depth. Its Trevo NXT thrombectomy technology boasts TICI 2b/3 recanalization rates over 85%, and its 2025 acquisition of Inari Medical (USD 4.9 billion) extended its spectrum of vascular intervention from neuro to peripheral VTE.

MicroVention (Terumo), whose FRED flow diverter and Headway micro-catheter portfolio capitalizes on Terumo's strong hospital ties throughout Japan, China, and Southeast Asia, is characterized by its geographic scale and Asia-Pacific distribution advantage. The competitive landscape has changed as a result of M&A-driven consolidation. For example, Boston Scientific's January 2026 acquisition of Penumbra for USD 14.5 billion represents the largest neurovascular transaction in history, and Medtronic's March 2026 acquisition of Scientia Vascular for USD 550 million fills a crucial access catheter gap in its portfolio.

Top 10 Global Neurovascular Devices Companies --- MRFR Rankings (2026)

MRFR has identified and profiled the following leading neurovascular devices companies globally, evaluated on the basis of revenue performance, geographic presence, product portfolio breadth, clinical evidence depth, innovation investment, and regulatory footprint. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of June 2026.

Detailed Company Profiles

1. Medtronic plc | NYSE: MDT | Dublin, Ireland

Medtronic's neurovascular position rests on a portfolio architecture that no competitor can replicate without a decade of clinical evidence accumulation. The company's Pipeline Flex embolization device and Solitaire X stent retriever span the two largest revenue segments — aneurysm coiling and ischemic stroke thrombectomy — giving it an estimated 18–22% global neurovascular revenue share. Medtronic's FY2025 total company revenue reached USD 33.5 billion per its SEC 10-K filing (fiscal year ended April 25, 2025).

In March 2026, Medtronic agreed to acquire Scientia Vascular for USD 550 million (plus milestones), filling a critical gap in neurovascular access catheters and guidewires used to navigate complex brain vasculature during stroke and aneurysm procedures. The January 2025 exclusive US distribution agreement with Contego Medical for the Neuroguard IEP integrated stent-balloon-filter platform extends Medtronic's reach into carotid artery stenting.

2. Stryker Corporation | NYSE: SYK | Portage, Michigan, USA

Stryker's neurovascular competitive edge is built on thrombectomy clinical performance data that creates physician switching costs. The Trevo NXT platform reports TICI 2b/3 recanalization rates exceeding 85%, a metric that drives hospital procurement decisions in competitive bids. Stryker reported total company revenue of USD 25.1 billion for FY2025, with its MedSurg and Neurotechnology segment growing 15.7% year-over-year.

The February 2025 acquisition of Inari Medical for USD 4.9 billion (USD 80/share) was transformative — Stryker subsequently renamed its Neurovascular business unit to 'Vascular,' reflecting the expanded scope from purely neurovascular into peripheral VTE thrombectomy. In Q2 2025, the Vascular segment generated USD 498 million in revenue, growing 52.3% year-over-year on a reported basis (per Medical Device Network analysis of Stryker Q2 2025 results). The Surpass Streamline flow diverter anchors Stryker's hemorrhagic stroke portfolio.

3. Boston Scientific Corporation | NYSE: BSX | Marlborough, Massachusetts, USA

Boston Scientific's January 2026 agreement to acquire Penumbra for USD 14.5 billion (USD 374/share) represents the largest neurovascular transaction in history and instantly vaults the company from a peripheral player to a top-three neurovascular force. Boston Scientific reported total net sales of USD 20.1 billion for FY2025, growing 19.9% on a reported basis, with R&D investment of USD 2.05 billion.

Prior to the Penumbra deal, Boston Scientific's neurovascular exposure was limited — the acquisition delivers Penumbra's Lightning aspiration system, SMART PACK coils, and computer-assisted vacuum thrombectomy (CAVT) platform, which generated USD 947.9 million in thrombectomy revenue alone in FY2025. The deal is pending regulatory review and expected to close by the end of 2026.

4. Penumbra, Inc. | NASDAQ: PEN (pending acquisition by Boston Scientific) | Alameda, California, USA

Penumbra's strategic value to Boston Scientific rests on its aspiration-first thrombectomy platform, which has shifted clinical practice away from stent retrievers in many stroke centers. The company reported total revenue of USD 1.40 billion for FY2025, an increase of 17.5% year-over-year, with thrombectomy products contributing USD 947.9 million (+16.2%) and embolization/access products contributing USD 455.7 million (+20.2%). R&D spend was USD 89.8 million.

Penumbra's Lightning Flash 3.0 and Lightning Bolt 12 systems, launched in 2025, advanced the CAVT technology platform. The company sells directly in the United States, most of Europe, Canada, Australia, and Singapore, with the US representing 77.8% of total revenue.

5. MicroVention, Inc. (Terumo Neuro) | Subsidiary of Terumo Corporation (TSE: 4543) | Aliso Viejo, California, USA

MicroVention's competitive moat is its flow-diverter innovation pipeline and Terumo's Asia-Pacific distribution density, which no Western neurovascular pure-play can replicate. The company's FRED flow diverter and Headway micro-catheter portfolio leverage Terumo's established hospital relationships across Japan, China, and Southeast Asia.

Terumo Corporation exceeded JPY 1.0 trillion in revenue for FY2024 (approximately USD 6.6 billion at prevailing exchange rates), though MicroVention's specific neurovascular revenue is not separately disclosed. In June 2024, Terumo launched the LVIS EVO intraluminal support device in the US market for wide-neck intracranial aneurysms. In May 2025, Terumo reorganized its division names, rebranding the Neurovascular Division as 'Terumo Neuro' (TN).

6. Johnson & Johnson (Cerenovus) | NYSE: JNJ | New Brunswick, New Jersey, USA

Johnson & Johnson's neurovascular position is defined by portfolio uncertainty rather than product weakness. The company's MedTech segment generated USD 31.9 billion in FY2024 revenue, but Cerenovus neurovascular revenue is not separately disclosed. Cerenovus markets the EMBOTRAP III stent retriever, Cascade micro-platform, and CEREGLIDE 71 aspiration catheter.

In February 2025, reports emerged that J&J is exploring the sale of Cerenovus in a deal valued at USD 1.0–1.5 billion, as the company streamlines its MedTech portfolio following the USD 13.1 billion Shockwave Medical acquisition in 2024. The potential divestiture signals a strategic retreat from neurovascular devices as J&J concentrates capital on cardiovascular and orthopaedic growth platforms.

7. Balt Group (BALT Extrusion) | Private | Montmorency, France

Balt Group's strategic position is that of a European niche leader in aneurysm coiling equipment, with a product portfolio that punches above its weight in flow-diverter and liquid embolic categories. The company is headquartered in Montmorency, France, and markets the SILK+ flow diverter, Squid liquid embolic system, and EXTRAFLOW aspiration catheter across 80+ countries. As a private company, Balt does not disclose audited financials. Its SILK flow diverter was among the first commercially available flow-diverter platforms in Europe, giving Balt a physician training legacy that sustains loyalty despite competition from Medtronic and MicroVention.

8. Phenox GmbH | Private | Bochum, Germany

Phenox's competitive differentiation is its German engineering focus on complex aneurysm morphologies that larger competitors often overlook. Founded in 2005, the company has grown to 225 employees per PitchBook data (as of 2022) and generates estimated annual revenue of USD 77.8 million per third-party estimates. Phenox markets the pRESET mechanical thrombectomy system, p64/p48 MW flow diverters, and the pCONUS implant for wide-neck bifurcation aneurysms — a niche indication where few competitors have dedicated solutions. Since 2020, Phenox has been the exclusive distributor of Wallaby Medical's Avenir Coiling System in Europe, creating a symbiotic relationship with the Chinese challenger. Subsidiaries operate in Galway (Ireland), Irvine (California), São Paulo (Brazil), and Milan (Italy).

9. MicroPort Scientific Corporation (MicroPort NeuroScientific) | HKEX: 00853 | Shanghai, China

MicroPort's neurovascular strategy is that of a Chinese domestic champion with an emerging export playbook. The parent company reported total group revenue of USD 994.9 million for FY2024. MicroPort NeuroScientific recorded segment revenue of USD 53.3 million in 1H 2025, with overseas revenue surging 67.4% year-over-year excluding foreign exchange impact. The company has commercialized 8 products in 34 overseas countries, covering 9 of the top 10 countries by global neurovascular surgery volume. Key products include the Tubridge flow diverter, NUMEN stent retriever, and NeuroHawk thrombectomy device (which received CE certification in 2025). Direct sales models in South Korea and North America are driving growth — North American revenue grew 145.8% year-over-year in 1H 2025.

10. Acandis GmbH | Private | Pforzheim, Germany

Acandis occupies a specialized position at the intersection of German precision engineering and neurovascular stent system innovation. The company is headquartered in Pforzheim, Germany, and markets the DERIVO flow diverter, APERIO thrombectomy device, and a portfolio of stent retrievers and micro-catheters across Europe, the Middle East, Asia, and Latin America. In January 2025, Acandis received a EUR 50 million growth investment from Lauxera Capital Partners, the first deployment from Lauxera Growth II fund, signaling private equity conviction in mid-tier neurovascular engineering firms. As a private company, Acandis does not disclose audited financials.

M&A Activity Tracker (2024–2026)

The Neurovascular Devices Market has experienced landmark consolidation as integrated medtech operators pursued inorganic growth to capture the converging thrombectomy, flow-diverter, and neurovascular access markets. Market Research Future tracks the following verified, named transactions directly relevant to the neurovascular devices market; entries that could not be corroborated against a dated public source have been removed from this tracker rather than retained as unverified placeholders.

Key Trend

MRFR analysis identifies consolidation of aspiration thrombectomy and neurovascular access capabilities into diversified interventional platforms as the dominant M&A theme. Boston Scientific's USD 14.5 billion Penumbra acquisition and Medtronic's USD 550 million Scientia Vascular deal both reflect a strategic imperative to own the full procedural stack — from access catheter to clot removal — rather than compete as component suppliers. A parallel theme is private equity's growing interest in mid-tier European neurovascular engineering firms, illustrated by Lauxera Capital's EUR 50 million investment in Acandis, as PE firms recognize the scarcity value of CE mark-ready flow-diverter manufacturing expertise.

R&D Investment & Innovation Signals

R&D and technology investment across the Neurovascular Devices Market has accelerated as operators invest in AI-guided catheter navigation, bioresorbable intracranial stents, robotic-assisted intervention platforms, and next-generation aspiration systems — addressing the primary operational constraints of first-pass recanalization rates, long-term foreign-body concerns, and operator radiation exposure that define competitive differentiation in the market.

• Medtronic: Medtronic continues to integrate the Scientia Vascular acquisition into its neurovascular pipeline, adding advanced guidewire and micro-catheter navigation capabilities for tortuous intracranial anatomy. The company's digital outcomes platform reportedly generated USD 85 million in recurring software revenue in 2024, signaling a shift toward procedural analytics monetization.

• Stryker: Stryker's Vascular segment (post-Inari acquisition) reported strong year-over-year revenue growth in Q2 2025, validating the cross-selling thesis between neuro and peripheral thrombectomy. The company is investing in robotic-assisted catheter navigation platforms that reduce fluoroscopy time.

• Boston Scientific / Penumbra: The pending acquisition will combine Boston Scientific's USD 2.05 billion annual R&D budget with Penumbra's CAVT technology platform. Penumbra's Lightning Flash 3.0 and Lightning Bolt 12 systems, launched in 2025, advanced aspiration thrombectomy efficacy and are expected to accelerate under Boston Scientific's global distribution.

• MicroVention (Terumo): Terumo's LVIS EVO intraluminal support device, launched in the US in June 2024, targets wide-neck intracranial aneurysms — a high-complexity segment where competitors have fewer dedicated solutions. The company is also advancing bioresorbable stent trials through its parent company's cardiovascular R&D infrastructure.

• Johnson & Johnson (Cerenovus): J&J's exploration of a Cerenovus sale (valued at USD 1.0–1.5 billion) has frozen near-term neurovascular R&D investment as the unit operates under strategic review. The CEREGLIDE 71 aspiration catheter, launched in 2024, remains the most recent major product introduction.